Evaluation of Intestinal Secretion of Antibodies and Auto-antibodies Associated With Crohn's Disease
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 160
- Locations
- 1
- Primary Endpoint
- Compare the performances of the dosage of the ASCA in floating it of culture of intestinal biopsies in that of their dosage in the serum
Study Overview
Brief Summary
We propose to study the intestinal secretion of ASCA by evaluating them in biopsy culture supernatants from a cohort of patients suffering from CD (n=80) and a cohort of control patients (UC (n=40) and patients without IBD (n=40 )).
Detailed Description
Its diagnosis is based upon clinical, endoscopic and histological parameters but recent studies have shown that seric evaluation of immunological markers (anti-Saccharomyces cerevisiae antibodies (ASCA), anti-neutrophil cytoplasmic auti-antibodies (ANCA)) could be useful. Crohn's disease (CD) is an inflammatory bowel disease (IBD) of the young people. Antibodies anti-chitobisoside carbohydrate (ACCA), anti-laminaribioside carbohydrate (ALCA) and anti-mannobioside carbohydrate (AMCA) have been described as new serological markers of CD.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Diagnostic
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients reached by disease of crohn
- •patients reached by hemorrhagic first side-colitis
Exclusion Criteria
- •Forms ileales or ano-périneales pure of disease of crohn
- •indefinite colitis
Arms & Interventions
1
Patients with crohn disease
Intervention: Blood sampling and biopsy (Other)
2
Patients reached by hemorrhagic first side-colitis
Intervention: Biopsy and blood sampling (Other)
3
Patients controls
Intervention: Biopsy and blood sampling (Other)
Outcomes
Primary Outcomes
Compare the performances of the dosage of the ASCA in floating it of culture of intestinal biopsies in that of their dosage in the serum
Time Frame: 24 months
Secondary Outcomes
- Determine if the patients reached by disease of crohn not presenting ASCA in their serum represent one under group of disease of crohn(24 months)